- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01470144
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension (Epitome2ext)
June 1, 2017 updated by: Actelion
An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)
This is an open-label, nonrandomized extension to study AC-066A301.
The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- Uz Gasthuisberg
-
-
-
-
Ontario
-
Toronoto, Ontario, Canada, M5G 2N2
- University of Toronto
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Sir Mortimer B Davis Jewish General Hospital
-
-
-
-
-
Caen, France
- CHU caen
-
Paris, France
- Hopital Kremlin Bicetre
-
-
-
-
-
Bologna, Italy, 40438
- Ospedale Sant'Orsola
-
-
-
-
-
Amsterdam, Netherlands
- VUMC
-
-
-
-
-
Madrid, Spain
- Hospital 12 de Octubre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent prior to initiation of any study-mandated procedure
- Patients who completed participation in study AC-066A301
- Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301
Exclusion Criteria:
- Patients who prematurely discontinued study drug in study AC-066A301
- Patients for whom continued treatment with EFI is no longer considered appropriate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Single arm, open-label
|
Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump.
The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment-emergent Adverse Events
Time Frame: On average 2.72 years
|
On average 2.72 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exposure Duration
Time Frame: On average 2.72 years
|
Duration of exposure to EFI
|
On average 2.72 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2011
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
October 28, 2011
First Submitted That Met QC Criteria
November 9, 2011
First Posted (Estimate)
November 11, 2011
Study Record Updates
Last Update Posted (Actual)
June 26, 2017
Last Update Submitted That Met QC Criteria
June 1, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-066A302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Epoprostenol
-
GlaxoSmithKlineCompletedHypertension, PulmonaryUnited States, Netherlands, Canada
-
National Center for Research Resources (NCRR)Baylor College of MedicineCompletedHypertension, Pulmonary
-
ActelionCompletedPulmonary Arterial HypertensionUnited States
-
Free University Medical CenterCompleted
-
ActelionCompletedPulmonary Arterial HypertensionUnited States
-
ActelionCompletedPulmonary Arterial HypertensionSpain, Belgium, France, Canada, Italy, Netherlands
-
Aerogen Pharma LimitedCompletedPulmonary HypertensionUnited States
-
Aerogen Pharma LimitedOhio State UniversityCompletedCOVID-19United States
-
Umeå UniversityCompletedTraumatic Brain InjurySweden
-
GlaxoSmithKlineCompletedCardiovascular Disease